Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient IL-2 and Interferon Alfa in Metastatic Cancer
NCT00002504Phase 2Completed
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Start
- Aug 1992
- Primary completion
- Feb 1998
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin and interferon alfa in metastatic cancer, sponsored by Hoag Memorial Hospital Presbyterian. Primary endpoint: Objective Response Rate at 8 weeks. Started Aug 1992; status: completed.
02
Drugs
aldesleukininterferon alfa
03
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT00002504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002504.